Prosecution Insights
Last updated: August 14, 2026

Hangzhou Dac Biotech Co. Ltd.

7 pending office actions • 5 art units • 5 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
5
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (14%)
1
Medium (14%)
5
Easy (71%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only4 (57%)
Double-patenting only1 (14%)
Double-patenting + other1 (14%)
Multi-statute (no §101)1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PUTTLITZ, KARL J 2 69.1% +18.5%
CANELLA, KAREN A 2 62.1% +32.9%
COUGHLIN, MATTHEW P 1 71.3% +12.0%
STONEBRAKER, ALYSSA RAE 1 56.9% +50.4%
BRAUN, MADELINE E 1 67.6% +26.4%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18156709 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS PUTTLITZ, KARL J 209d overdue

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18156709 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS PUTTLITZ, KARL J 209d overdue
17622360 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS PUTTLITZ, KARL J 37d overdue
17284091 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP STONEBRAKER, ALYSSA RAE 17d overdue
17426813 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS CANELLA, KAREN A 15d overdue
17256034 A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES BRAUN, MADELINE E 19d
18001899 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CANELLA, KAREN A
17389922 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE COUGHLIN, MATTHEW P

Top Art Units

Art UnitApps
1646 2
1643 2
1626 1
1642 1
1624 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18156709 CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS PUTTLITZ, KARL J 1646 §103§112Other Non-Final OA 209d overdue Pending Jan 19, 2023
18001899 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CANELLA, KAREN A 1643 §102DP Final Rejection Pending Dec 15, 2022
17622360 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS PUTTLITZ, KARL J 1646 §112 Non-Final OA 37d overdue Pending Dec 23, 2021
17389922 CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE COUGHLIN, MATTHEW P 1626 §112 Final Rejection Pending Jul 30, 2021
17426813 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS CANELLA, KAREN A 1643 §112 Non-Final OA 15d overdue Pending Jul 29, 2021
17284091 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP STONEBRAKER, ALYSSA RAE 1642 DP Non-Final OA 17d overdue Pending Apr 09, 2021
17256034 A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES BRAUN, MADELINE E 1624 §112 Non-Final OA 19d Pending Dec 24, 2020

Managing Hangzhou Dac Biotech Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month